Alnylam Pharma (ALNY) Misses Q4 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. GNK
2. AZN
3. SPY
4. HIVE
5. GSAT
6. S
7. EXE
8. DSX
9. ALH
10. SERV

Go back to Alnylam Pharma (ALNY) Misses Q4 EPS by 13c

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity

February 10, 2022 8:00 AM EST

Achieved Fourth Quarter and Full Year 2021 Global Net Product Revenues of $199 Million and $662 Million, Respectively, Representing 83% Annual Growth Compared to 2020

Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy

Provides 2022 Combined Net Product Revenue Guidance of $900 Million to $1 Billion, in Addition to Collaboration & Royalty Revenue and Operating Expense Guidance

CAMBRIDGE, Mass.--(BUSINESS... More